PURPOSE: Neuroblastoma (NB) is treated with surgery, chemotherapy and radiotherapy. We assessed the effects of surgical resection on the outcome over a 23-year period at our institution. METHODS: 85 children were included with a median age at diagnosis of 2.0 (range 0.1-15) years. We assessed the correlation of the complete surgical resection (CR) rate, metastases, NMYC amplification (NMYCA) and chemotherapeutic response with the 5-year overall survival (OS). RESULTS: The INSS stage of NB was 1 in 11 (13 %) patients, 2 in 10 (11 %), 3 in 13 (17 %), 4 in 46 (53 %) and 4S in five patients (6 %). Fifty-two (61 %) patients had high-risk NB and 22 (26 %) had NMYCA. The resection was complete in 72 (85 %) patients, incomplete (ICR) in seven (8 %) and six (7 %) patients did not undergo surgery. Fifty-five patients were administered neoadjuvant and 61 were administered adjuvant chemotherapy (high-dose, n = 50). The OS (5 year) was 68 %: stage 1 (100 %), 2 (90 %), 3 (77 %), 4 (52 %), 4S (80 %) and high-risk NB (52 %). The OS in high-risk NB patients was correlated with a good chemotherapeutic response of the primary tumour, with a RR for mortality = 0.3 (95 % CI 0.1-0.7; p = 0.01), but not with the CR, which had an RR = 0.9 (95 % CI 0.3-2.4; p = 0.84). CONCLUSIONS: The OS in high-risk NB patients was related to a good histological chemotherapeutic response, but not with complete excision of the primary tumour.
PURPOSE:Neuroblastoma (NB) is treated with surgery, chemotherapy and radiotherapy. We assessed the effects of surgical resection on the outcome over a 23-year period at our institution. METHODS: 85 children were included with a median age at diagnosis of 2.0 (range 0.1-15) years. We assessed the correlation of the complete surgical resection (CR) rate, metastases, NMYC amplification (NMYCA) and chemotherapeutic response with the 5-year overall survival (OS). RESULTS: The INSS stage of NB was 1 in 11 (13 %) patients, 2 in 10 (11 %), 3 in 13 (17 %), 4 in 46 (53 %) and 4S in five patients (6 %). Fifty-two (61 %) patients had high-risk NB and 22 (26 %) had NMYCA. The resection was complete in 72 (85 %) patients, incomplete (ICR) in seven (8 %) and six (7 %) patients did not undergo surgery. Fifty-five patients were administered neoadjuvant and 61 were administered adjuvant chemotherapy (high-dose, n = 50). The OS (5 year) was 68 %: stage 1 (100 %), 2 (90 %), 3 (77 %), 4 (52 %), 4S (80 %) and high-risk NB (52 %). The OS in high-risk NB patients was correlated with a good chemotherapeutic response of the primary tumour, with a RR for mortality = 0.3 (95 % CI 0.1-0.7; p = 0.01), but not with the CR, which had an RR = 0.9 (95 % CI 0.3-2.4; p = 0.84). CONCLUSIONS: The OS in high-risk NB patients was related to a good histological chemotherapeutic response, but not with complete excision of the primary tumour.
Authors: Barrie S Rich; Maureen P McEvoy; Natasha E Kelly; Edwin Oh; Sara J Abramson; Anita P Price; Nai-Kong V Cheung; Michael P La Quaglia Journal: J Pediatr Surg Date: 2011-01 Impact factor: 2.545
Authors: Victoria Castel; J A Tovar; E Costa; J Cuadros; A Ruiz; V Rollan; J I Ruiz-Jimenez; R Perez-Hernández; A Cañete Journal: J Pediatr Surg Date: 2002-11 Impact factor: 2.545
Authors: Frank Berthold; Joachim Boos; Stefan Burdach; Rudolf Erttmann; Günter Henze; Johann Hermann; Thomas Klingebiel; Bernhard Kremens; Freimut H Schilling; Martin Schrappe; Thorsten Simon; Barbara Hero Journal: Lancet Oncol Date: 2005-09 Impact factor: 41.316
Authors: Ulla M Saarinen-Pihkala; Liisa Hovi; Antti Koivusalo; Kirsi Jahnukainen; Riitta Karikoski; Hannu Sariola; Sakari Wikström Journal: Pediatr Blood Cancer Date: 2012-04-10 Impact factor: 3.167
Authors: Katherine K Matthay; C Patrick Reynolds; Robert C Seeger; Hiroyuki Shimada; E Stanton Adkins; Daphne Haas-Kogan; Robert B Gerbing; Wendy B London; Judith G Villablanca Journal: J Clin Oncol Date: 2009-01-26 Impact factor: 44.544
Authors: G M Brodeur; J Pritchard; F Berthold; N L Carlsen; V Castel; R P Castelberry; B De Bernardi; A E Evans; M Favrot; F Hedborg Journal: J Clin Oncol Date: 1993-08 Impact factor: 44.544
Authors: Jon Pritchard; Simon J Cotterill; Shirley M Germond; John Imeson; Jan de Kraker; David R Jones Journal: Pediatr Blood Cancer Date: 2005-04 Impact factor: 3.167
Authors: T Iehara; H Hosoi; K Akazawa; Y Matsumoto; K Yamamoto; S Suita; T Tajiri; T Kusafuka; E Hiyama; M Kaneko; F Sasaki; T Sugimoto; T Sawada Journal: Br J Cancer Date: 2006-05-22 Impact factor: 7.640